SAB Biotherapeutics stockholders elect four Class II directors, ratify auditor at 2026 annual meeting

SAB Biotherapeutics, Inc.

David Zaccardelli, Katie Ellias, David Link, and Andrew Moin elected as Class II directors with 48.3M, 48.3M, 44.1M, and 44.2M votes for, respectively.
EisnerAmper LLP ratified as independent auditor for FY2026: 59.3M votes for, 3,373 against, 26,798 abstentions.
Quorum of 59.3M shares (76.12% of outstanding) present at June 18, 2026 meeting.
Broker non-votes of 10,994,436 on director elections.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.99

SAB Biotherapeutics, Inc. shareholders approved Election of Dr. David Zaccardelli, Pharm.D., Katie Ellias, David Link, MBA, and Andrew Moin, as Class II directors to serve for a term of three years at the 2026-06-18 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-06-18

Exact text from the filing

Proposal 1 : Election of four Class II directors Director Votes For Withheld Broker Non-Votes David Zaccardelli, Pharm.D. 48,352,114 2,984 10,994,436 David Link, MBA 44,083,923 4,271,175 10,994,436 Katie Ellias 48,350,086 5,012 10,994,436 Andrew Moin 44,157,704 4,197,394 10,994,436

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.99

SAB Biotherapeutics, Inc. shareholders approved Ratify the appointment of EisnerAmper LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026 at the 2026-06-18 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-06-18

Exact text from the filing

Proposal 2: Ratification of the appointment of EisnerAmper LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 Votes For Votes Against Abstentions 59,319,363 3,373 26,798

View on SEC.gov

1183 shareholder votes filed in the last 30 days. Browse all shareholder votes →

SAB Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-275976

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.